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Our objective was to evaluate the feasibility of a molecular assay based on a real-time PCR technique,
carried out with a LightCycler instrument (Roche Biochemicals), to identify Mycobacterium tuberculosis bacilli
and to detect rifampin and isoniazid resistance in DNA extracts from sputum samples. We studied three genes:
rpoB, which is associated with rifampin resistance, and katG and inhA, which are associated with isoniazid
resistance. A total of 205 sputum samples collected from 108 patients diagnosed with pulmonary tuberculosis
with positive auramine-rhodamine-staining (AR) sputum samples, were tested. The sensitivities of the Light-
Cycler PCR assay for the positive AR specimens was 97.5% (200 of 205) for rpoB and inhA genes and 96.5% (198
of 205) for the katG gene. For the total number of patients tested, the sensitivity was 100% (108 of 108 patients)
for rifampin, whereas the sensitivity was 98.1% (106 of 108 patients) for isoniazid. Full agreement was found
with the Bactec MGIT 960 method and the genotype inferred from the LightCycler data for rifampin. The
phenotypic method for isoniazid reported 13 resistant strains (>0.1 g/ml). In seven (53.8%) strains there was
a concordance between both methods, but we found that six (46.2%) strains reported as resistant by the
phenotypic method were determined to be susceptible by real-time PCR. For the 75 strains reported as
susceptible by the phenotypic method, the concordance with the LightCycler data was 100%. Our results
demonstrate that rifampin-resistant M. tuberculosis could be detected in DNA extracted from auramine-
rhodamine-positive sputum samples in a single-tube assay that took less than 3 h to perform for a collection
of auramine-rhodamine-positive specimens obtained from patients with culture-documented pulmonary tu-
berculosis. Similarly, this occurs in half of the isoniazid-resistant M. tuberculosis DNA extracted from aura-
mine-rhodamine-positive specimens.
Mycobacterium tuberculosis remains a serious public health
threat. According to the most recent data reported by the
World Health Organization, one-third of the world’s popula-
tion is infected with tuberculosis, and each year nearly two
million people dye from this disease. If current control efforts
are not massively expanded, tuberculosis will kill more than 40
million people over the next 25 years (27, 28). Early diagnosis,
effective treatment, and successful cessation of transmission
are major strategies in the control of tuberculosis.
Current treatment for tuberculosis is a multidrug regimen
based on rifampin and isoniazid, the drugs most efficient
against M. tuberculosis infection. Although use of the appro-
priate drug with full patient compliance is highly effective in
curing pulmonary tuberculosis, the emergence of M. tubercu-
losis strains that are resistant to rifampin and isoniazid reduces
the efficacy of standard treatment (9). This fact, and the asso-
ciation of tuberculosis with outbreaks (4, 6, 16), shows that
rapid diagnosis of active tuberculosis and early detection of
resistant strains are essential for effective patient management
and implementation of infection control measures.
Due to the slow-growth of M. tuberculosis bacilli, delays in
the detection of resistance strains can occur when conven-
tional phenotypic assays are used. Nucleic acid amplifica-
tion-based techniques are potentially the most rapid and
sensitive methods for detection, identification, and suscep-
tibility testing and are theoretically able to provide a same-
day diagnosis from clinical samples (10, 15, 17, 19). These
methods can potentially reduce the diagnostic time from
weeks to days (20).
The molecular basis of antitubercular drug resistance in M.
tuberculosis is becoming clearer. More than 96% of rifampin-
resistant strains have mutations in an 81-bp “core region” of
the rpoB gene, which encodes the  subunit of the RNA poly-
merase (10, 21), and the majority of isoniazid-resistant strains
have been found to contain mutations in codon 315 of the katG
gene, which encodes the catalase-peroxidase (30), or mutations
in the inhA ribosomal binding site (1). Different genotypic
approaches have been developed for the detection of resis-
tance in M. tuberculosis (5, 7, 18, 22).
In the present study we evaluate the use of a real-time PCR
technique, using the LightCycler system (Roche Biochemi-
cals), to identify M. tuberculosis bacilli and to detect rifampin
and isoniazid resistance in DNA extracts from auramine-rho-
damine-positive sputum samples obtained from tuberculous
patients. We studied three genes—rpoB, which is associated
with rifampin resistance, and katG and inhA, which are asso-
ciated with isoniazid resistance—because previous studies
demonstrated that the most frequent mutations found in ri-
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fampin- and/or isoniazid-resistant strains of M. tuberculosis in
our region were in those genes (8).
MATERIALS AND METHODS
Clinical samples collection and processing. We processed 205 sputum samples
obtained from 108 patients diagnosed with pulmonary tuberculosis according to
the radiological and clinical criteria described by Catanzaro et al. (3), with
documented positive auramine-rhodamine slides, attended at the HH UU Vir-
gen del Rocío in Seville, Spain, between 2000 and 2001. A total of 85 samples had
an acid-fast bacillus count of one to nine per ten fields in the smear, 97 samples
had one to nine bacilli per field, and 23 samples had more than nine bacilli per
field. The specimens were liquefied and decontaminated with an equal volume of
N-acetyl-L-cysteine and 2% NaOH, homogenized by centrifugal swirling, and
then incubated for 15 min (14). The reaction was neutralized by adding 0.067 M
phosphate-buffered saline (pH 6.8), which resulted in a final volume of 50 ml.
The specimens were concentrated by centrifugation at 3,000  g for 15 min. The
supernatant was discarded, and the sediment was resuspended in 5 ml of sterile
water. Part of the sediment from each specimen was used to inoculate a Löwen-
stein-Jensen solid medium and to prepare a smear for auramine-rhodamine
staining (AR), whereas the remaining portion was stored at 20°C until use for
DNA extraction.
Löwenstein-Jensen slants were incubated at 37°C for 6 weeks and inspected
weekly for growth. When growth was detected, a smear was prepared to confirm
the presence of acid-fast bacilli from suspect colonies by Ziehl-Neelsen staining.
M. tuberculosis strains and drug susceptibility testing. We studied 88 clinical
isolates retrieved from the processed sputum samples from 88 different patients.
Isolates were identified by DNA probes (AccuProbe; Gen-Probe, Inc., San Di-
ego, Calif.) for M. tuberculosis complex, M. avium, M. gordonae, and M. kansasii.
The drug susceptibilities of all isolates were determined by the nonradiometric
dilution method Bactec MGIT 960 (29).
Sample preparation. Purified DNA of M. tuberculosis H37Rv and from other
seven Mycobacterium species were also used in the assay. The species were as
follows: M. bovis, M. avium, M. intracellulare, M. kansasii, M. fortuitum, M.
chelonae, M. marinum. The different strains were grown on Löwenstein-Jensen
slants and the DNA was prepared from one or two colonies by chloroform-
isoamyl extraction as previously described (25). Between 0.1 and 1 ng of DNA
was used as the template for each PCR assay, to mimic the concentration
expected to occur in sputum samples.
The sputum samples were inactivated by heating at 80°C for 30 min, and 1-ml
sputum samples were taken. The samples were extracted by DNA IV (Unipath
S.A., Oxoid, Spain) method according to the instructions of the manufacturer.
After decontamination and before the DNA extraction, we added human
chromosomal DNA (final concentration, 10 ng/l) in all of the sputum samples
tested to monitor the nucleic acid recovery during specimen preparation and the
presence of PCR inhibitors by amplification with the -globin primers GH20 and
PC04. A sputum sample, smear and culture negative, was processed along with
the rest of the sputa to control contamination during sample processing. No
contamination was detected.
LightCycler real-time PCR. All DNA extracts were amplified with the primers
used in conventional PCR, with the addition of the fluorescein and Red 640-
labeled probes to the amplification mix. Four different pairs of the probes were
used, rpo1 anchor-sensor that covered the region containing codons 526 and 531
of the rpoB gene (22), rpo2 anchor-sensor that covered the region containing
codons 510 to 528 of the rpoB gene (23), kat1 anchor-sensor that covered the
region containing codon 315 of the katG gene (22), and inh1 anchor-sensor that
detected nucleotide substitution C209T in the regulatory region of the inhA gene
(23). All primers and hybridization probes were synthesized by TIB MOLBIOL
(DNA Synthesis Service; Roche Diagnostics, Berlin, Germany). The probes were
designed to detect certain mutations based on previous studies (8, 24).
The components for PCR in a final volume of 20 l included 2 l of a
commercial ready-to-use reaction mix for PCR (LightCycler-DNA master hy-
bridization probes; Roche Diagnostics) that contains TaqDNA polymerase, re-
action buffer, a deoxynucleoside triphosphate mix, and 10 mM MgCl2. We added
MgCl2 to a final concentration of 4 mM. The primers and probes were added to
final concentrations of 0.5 and 0.2 M, respectively. Finally, we used 5 l of the
corresponding template DNA. The 20 l (final volume) reaction mix was placed
in glass capillary cuvettes, which were filled by pulse centrifugation in a micro-
centrifuge. In each set of experiments we always included negative as well as
positive controls. The negative control sample was prepared by replacing the
template DNA with PCR grade water. The positive control sample was prepared
by adding 2 l of genomic DNA from M. tuberculosis H37Rv (susceptible strain)
to the reaction mix. Conditions for cycling were 95°C for 45 s, followed by 45
cycles of 95°C for 1 s, 55°C (annealing temperature for the rpoB gene) and 60°C
(annealing temperature for the katG and inhA genes) for 2 s, and 72°C for 6 s,
with fluorescence monitoring during the annealing phase; this, in turn, was
followed by a melting program of 50 to 85°C at 0.1°C/s, with continuous moni-
toring of the fluorescence.
For -globulin gene amplification we used LC-Sybrgreen I method that in-
cluded, in a final volume of 20 l, 2 l of a ready-to-use reaction mix for PCR
(LightCycler-DNA Master Sybrgreen), with the same components as before and
Sybrgreen I. We added MgCl2 until a final concentration of 4 mM and primers
GH20 and PC04 to a final concentration of 0.5 M. The conditions for cycling
were also the same except for the annealing temperature (55°C) and the fluo-
rescence monitoring that was done at the end of the amplification phase. The
melting program started at 50°C and ended at 95°C.
RESULTS
Analytical sensitivity and specificity. The sensitivity of the
assay in water with mycobacterial DNA from the wild-type M.
tuberculosis H37Rv or from a mutant isolate was 1 pg (corre-
sponding to 200 mycobacterial genomes) for the rpoB primers
and probes or 0.1 pg (corresponding to 20 mycobacterial ge-
nomes) for the katG and inhA primers and probes.
To determine whether the assay is specific for M. tuberculo-
sis, we tested DNA that was isolated from seven different
mycobacterial species. The results show that only M. tubercu-
losis and the closely related M. bovis (a member of the M.
tuberculosis group, all of which cause tuberculosis) elicited a
positive response for the katG and inhA probes. Although the
rpoB probes gave positive results with all mycobacterial spe-
cies, the melting temperature (Tm) were low enough to differ-
entiate M. tuberculosis and M. bovis, with identical Tm values,
from the remaining species (data not shown).
Genotypic assays by real-time PCR. Fluorescence measure-
ments were made in every cycle. The threshold cycle (Ct) is the
cycle at which there is a significant increase in fluorescence,
and this value is associated with the exponential growth of the
PCR product during the log-linear phase. Table 1 shows the
CT values for the katG gene versus auramine-rhodamine
counts to provide an idea of the analytical sensitivity of the
assay.
Table 2 shows the detection of M. tuberculosis DNA by
real-time PCR according to the auramine-rhodamine bacillus
count in the smear. A total of 205 sputum samples collected
from 108 patients diagnosed with pulmonary tuberculosis and
with positive AR smears were tested. Two hundred samples
(97.5%) were determined to be positive by LightCycler PCR
assays when rpo1, rpo2, and the inh pair of probes were used,
whereas with the kat1 pair of probes 198 (96.5%) specimens
were determined to be positive by LightCycler PCR. Five sam-
ples from five different patients were determined to be nega-
TABLE 1. Cycling numbers (Ct values) for Light Cycler








Mean Median Minimum Maximum SD SE
1 to 9/10 fields 83 30.11 30.26 26.26 33.83 1.61 0.21
1 to 9/field 93 27.11 27.71 19.75 34.55 3.44 0.40
9/field 22 23.91 22.62 19.79 29.64 3.51 0.85
a As determined by fluorescence microscopy (magnification,  400).
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tive by LightCycler PCR when all pair of probes were used.
These samples were tested a second time and remained neg-
ative. We believe this result was due to a failed DNA extrac-
tion, since each patient provided other specimens that were
positive in other PCR assays, and the AR counts in the smear
were one to nine per field (at a magnification of 400) or more
in four of them and one to nine per 10 fields in the other.
Furthermore, positive results with -globulin primers have
been found in all of the samples, indicating the absence of PCR
inhibitors in the specimens. Two culture-negative samples
from two different patients that were determined to be nega-
tive by LightCycler PCR when the kat1 pair of probes were
used were determined to be positive when rpo1, rpo2, and the
inh1 pair of probes were used; this could be explained by a
partial deletion of the katG gene in these two strains. These
two patients had auramine-rhodamine bacillus counts of one to
nine per 10 fields and one to nine per field in the smear
(magnification, 400), respectively, and no more specimens to
be tested.
A comparison of amplification assays and culture results is
shown in Table 2. M. tuberculosis was isolated from 159 AR-
positive sputa; M. kansasii was isolated from 3 AR-positive
sputa from the same patient and excluded from the study. In
these three sputa, very low Tm values for the rpoB gene were
found (55.1°C for the rpo1 probes and 55.9°C for the rpo2
probes) and no amplification with the katG and inhA genes was
observed. These data are not included in Table 3. A total of
192 (96%) samples were found to contain strains susceptible to
rifampin, and 185 (93.4%) samples were found to contain
strains susceptible to isoniazid (0.1 g/ml), according to its
Tm as previously described (24). Eight (4%) samples were
found to contain strains resistant to rifampin. A mutation at
codon 516 of the rpoB gene was found in four of them, whereas
a mutation at the region containing codons 526 and 531 of the
rpoB gene was found in the remaining four samples. These
eight rifampin-resistant samples were obtained from four pa-
tients. Resistance to isoniazid was directly detected in 13
(6.6%) samples collected from seven patients. All of them
showed a mutation at the codon 315 of the katG gene.
Phenotypic assays by the nonradiometric dilution method.
Of the 108 patients studied, 88 clinical isolates retrieved from
the processed sputum samples of 88 different patients were
tested (Table 4). Full agreement was found with the Bactec
MGIT 960 method and the genotype inferred from the Light-
Cycler data when the rpo1 and rpo2 pair of probes was used.
The phenotypic method for isoniazid reported 13 resistant
strains (0.1 g/ml). In seven (53.8%) strains there was a
concordance between both methods, but we found that six
(46.2%) strains reported as resistant by the phenotypic method
were determined to be susceptible by real-time PCR when the
TB pair of probes and the inh pair of probes were used. For the
TABLE 2. Detection of M. tuberculosis DNA from auramine-





No. of samples with the indicated result by:
rpoB PCR katG PCR inhA PCR
Positive Negative Positive Negative Positive Negative
1 to 9/10 fields 85 84 1 83 2 84 1
1 to 9/field 97 94 3 93 4 94 3
9/field 23 22 1 22 1 22 1
Total 205 200 5 198 7 200 5
a See Table 1, footnote a.
TABLE 3. Results for 205 respiratory specimens from 108 patients: comparison of PCR amplification assays with culture results
Patient statusa No. ofsamples
No. of isolates with indicated result by:







Resistant Susceptible Resistant Susceptible Resistant Susceptible
Smear positive, culture
positive








15 0 15 0 0 15 0 0 15 0
Total 205 8 192 5 13 185 7 0 200 0
a TB, tuberculosis.
TABLE 4. Results of susceptibility testing of 88 clinical isolates:
comparison of PCR amplification assays with the Bactec MGIT
960 method
Drug and method
No. of isolates (%) that were:
Susceptible Resistant
Rifampin
MGIT 84 (95.5) 4 (4.5)
PCR with:
rpo1 probe 85 (96.6) 3 (3.4)
rpo2 probe 87 (98.9) 1 (1.1)
Isoniazid
MGIT 75 (85.2) 13 (14.8)
PCR with:
kat1 probe 81 (92) 7 (8.0)
inh1 probe 88 (100) 0 (0)
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75 strains determined to be susceptible by the phenotypic
method, the concordance with the LightCycler data was 100%.
Sensitivity and specificity of LightCycler real-time PCR.
The sensitivity of the LightCycler PCR assay for the positive
AR specimens was 97.5% (200 of 205) when the rpo1 and rpo2
pair of probes and the inh probes were used and 96.5% (198 of
205) when the TB pair of probes was used. For all 108 patients
tested, the sensitivity was 100% with rpo1, rpo2, and the inh
pair of probes, whereas the sensitivity was 98.1% (106 of 108)
with the TB pair of probes.
The ability to detect true resistance or susceptibility and the
specificity of the rifampin genotypic method were 100%, since
this approach classified correctly all of the 88 strains tested by
the Bactec MGIT 960 method. The ability to detect the true
resistance and specificity of the isoniazid genotypic method
were 53.8 and 100%, respectively. The positive predictive value
and the negative predictive value of the isoniazid genotypic
method were 100 and 92.6%, respectively.
DISCUSSION
Our results demonstrate that rifampin-resistant M. tubercu-
losis can be detected in DNA extracted from positive AR
sputum samples in a single-tube assay that takes less than 3 h
to perform. Similarly, this occurs in half of the isoniazid-resis-
tant M. tuberculosis DNA extracted from auramine-rhoda-
mine-positive sputum samples by using the katG and inhA
probes. A major drawback of direct detection of rifampin-
resistant and/or isoniazid-resistant M. tuberculosis in sputa by
other molecular methods is the lack of sensitivity (11), but we
have not found such problems because we extracted M. tuber-
culosis DNA after decontamination of the sputa by the N-
acetyl-NaOH method, although this could be a problem with
other types of clinical samples such as pleural fluid. For isoni-
azid resistance, the sensitivity of the method is only 53.8%. As
with other genotype-based resistance prediction tests, a draw-
back in characterizing katG codon 315 mutations and inhA
mutations, as well as emb mutations for ethambutol resistance,
is that no prediction can be made for samples containing the
nonmutated genotypes (19). Therefore, the diagnostic catego-
ries cannot be “resistant” and “sensitive” but must be “resis-
tant” and “no prediction possible.” For these reasons, it is
open to debate whether a rapid resistance prediction test with
high specificity but low sensitivity is useful. The answer may
depend of the current alternative, which means waiting for
several weeks to detect isoniazid resistance by culture in all
affected patients rather that detecting half of these cases within
few hours. In addition, the mutations at codon 315 of the katG
gene have been associated with a high level of isoniazid resis-
tance (26), and thus the positive results obtained by this assay
are more clinically useful. The mutation detection allows for a
rapid result for resistance but not for susceptibility, and this
rapid result may have value for the physician; however, for the
testing of other antimicrobial agents and for all samples that
are negative for mutations, backup culture for susceptibility
testing would still be required.
This method could be used in combination with any of the
previously described methods to identify M. tuberculosis (12,
13, 15), and the simultaneous identification and detection of
rifampin and isoniazid resistance in AR-positive sputa is pos-
sible.
Our results demonstrate that it is possible to implement
real-time PCR in the diagnostic laboratory for the routine
detection of M. tuberculosis from sputa and probably from
liquid medium cultures. Slide microscopy for the detection of
acid-fast bacilli is a convenient and economical test used for
the determination of M. tuberculosis infection. However, recent
studies have shown that up to half of the new cases of tuber-
culosis are smear negative (2). Although we have not deter-
mined the clinical specificity of the assay because we have
included only auramine-rhodamine-positive sputa, this method
could be applied directly to acid-fast bacilli smear-negative
sputa from patients diagnosed with tuberculosis, especially in
patients showing poor treatment compliance and with clinical
relapses, among whom there is a high probability of resistant
M. tuberculosis strain isolation.
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